Literature DB >> 21902577

Lenalidomide: a new treatment option for Castleman disease.

Petr Szturz, Zdeněk Adam, Jana Chovancová, Olga Stehlíková, Martin Klabusay, Zdeněk Rehák, Renata Koukalová, Marta Krejčí, Luděk Pour, Lenka Zahradová, Roman Hájek, Jiří Mayer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21902577     DOI： 10.3109/10428194.2011.621564

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  4 in total

1.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

Review 2.  Update and new approaches in the treatment of Castleman disease.

Authors:  Kah-Lok Chan; Stephen Lade; H Miles Prince; Simon J Harrison
Journal:  J Blood Med       Date:  2016-08-03

3.  Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.

Authors:  Sisi Cai; Zhaodong Zhong; Xiang Li; Hong Xiang Wang; Li Wang; Min Zhang
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

4.  Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study.

Authors:  Yi Zhang; Shan-Shan Suo; Han-Jin Yang; Xin-Ping Zhou; Liang-Shun You; Wen-Juan Yu; Zhao-Ming Wang; Jie Jin
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-14       Impact factor: 4.553
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.